menu
    • menu
    [{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Semaglutide","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Cagrilintide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||Amylin\/calcitonin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Cagrilintide

    Menu

    Cagrilintide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Novo Nordisk

    Denmark arrow
    ICHH-25
    Not Confirmed

    Novo Nordisk

    Denmark arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cagrilintide,Semaglutide

    Therapeutic Area : Nutrition and Weight Loss

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CagriSema Shows Superior Weight Loss in REDEFINE 2 Trial for Obesity & Diabetes

    Details : CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.

    Product Name : CagriSema

    Product Type : Peptide

    Upfront Cash : Inapplicable

    March 10, 2025

    Lead Product(s) : Cagrilintide,Semaglutide

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Novo Nordisk

    Denmark arrow
    ICHH-25
    Not Confirmed

    Novo Nordisk

    Denmark arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cagrilintide,Semaglutide

    Therapeutic Area : Nutrition and Weight Loss

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    CagriSema Demonstrates Superior Weight Loss in Adults with Obesity in REDEFINE 1 Trial

    Details : CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide and semaglutide. It is being investigated for adults with overweight or obesity.

    Product Name : Undisclosed

    Product Type : Peptide

    Upfront Cash : Not Applicable

    December 20, 2024

    Lead Product(s) : Cagrilintide,Semaglutide

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Novo Nordisk

    Denmark arrow
    ICHH-25
    Not Confirmed

    Novo Nordisk

    Denmark arrow
    ICHH-25
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Semaglutide,Cagrilintide

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Novo Nordisk Successfully Completes Phase 2 Trial With Cagrisema in People With Type 2 Diabetes

    Details : People treated with CagriSema (semaglutide) achieved a numerically higher body weight reduction of 15.6% compared to a reduction of 5.1% for people treated with semaglutide and 8.1% with cagrilintide alone.

    Product Name : CagriSema

    Product Type : Peptide

    Upfront Cash : Not Applicable

    August 22, 2022

    Lead Product(s) : Semaglutide,Cagrilintide

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth